HPV-Specific T-Cell Generation via IL-7 and IL-15 Stimulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating HPV-specific T-cells are inefficient and lack specificity for HPV16 and HPV18 antigens, which are crucial for treating HPV-associated diseases, including cancers, as they often require specific cytokine combinations and stimulation protocols that are not consistently effective.
Innovation Solution
A method involving the stimulation of peripheral blood T-cells with antigen-presenting cells in the presence of IL-7 and IL-15, with optional co-stimulatory cells, and exposure to peptides corresponding to HPV antigens such as E6 and E7, to produce therapeutic T-cells that target HPV16 and HPV18, allowing for the expansion of T-cell populations specific to these antigens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cytokine combinations (IL-6, IL-7, IL-12, IL-15) are used for T-cell stimulation, then T-cell expansion can be achieved, but the method lacks specificity for HPV16 and HPV18 antigens and requires complex cytokine protocols
Solution Approach 1:
The patent extracts and eliminates unnecessary cytokines (IL-6 and IL-12) from the conventional four-cytokine combination, retaining only IL-7 and IL-15. This simplification maintains T-cell expansion capability while removing complexity from the protocol and improving specificity for HPV16 and HPV18 antigens through a streamlined cytokine environment.
Solution Approach 2:
The patent changes the cytokine parameter configuration by reducing the number of cytokines from four (IL-6, IL-7, IL-12, IL-15) to two (IL-7, IL-15). This parameter modification simplifies the stimulation protocol while maintaining or enhancing the effectiveness of HPV-specific T-cell generation.
2Productivity
If multiple cytokines are used for T-cell expansion, then T-cell population can be increased, but the process becomes less efficient and harder to control
Solution Approach 1:
The patent removes redundant cytokines (IL-6 and IL-12) from the stimulation protocol, keeping only the essential IL-7 and IL-15. This extraction maintains T-cell expansion productivity while significantly reducing protocol complexity and improving process control.
Solution Approach 2:
The patent modifies the cytokine parameter set by reducing the number of cytokines from four to two, which simplifies the stimulation protocol and makes the T-cell expansion process more efficient and easier to control while maintaining productivity.
3Reliability
If conventional stimulation methods are used, then some T-cell response can be obtained, but the fold expansion is limited and consistency is poor
Solution Approach 1:
The patent changes the cytokine parameter configuration from a four-cytokine mix to a two-cytokine combination (IL-7 and IL-15), which improves both the consistency and fold expansion of HPV-specific T-cell responses. This parameter optimization creates a more reliable and reproducible stimulation protocol.
Solution Approach 2:
The patent uses a focused, partial approach by selecting only the two most critical cytokines (IL-7 and IL-15) rather than applying all four conventional cytokines. This partial action achieves better consistency and expansion by concentrating on the essential factors without the interference of redundant or potentially detrimental cytokines.
Data Source
AI summary
Embodiments of the disclosure concern methods and compositions for immunotherapy for human papillomavirus infection and diseases associated therewith. In specific embodiments, methods concern production of immune cells that target one or more antigens of HPV16 and/or HPV18, including methods with stimulation steps that employ IL-7 and IL-15, but not IL-6 and/or IL-12. Other specific embodiments utilize stimulations in the presence of certain cells, such as costimulatory cells and certain antigen presenting cells.